IYH
Eli Lilly acquires AtaiBeckley for $3.8B, targeting depression with psychedelic drugs
Eli Lilly agreed to acquire biopharmaceutical firm AtaiBeckley for up to $3.8 billion. The deal marks Lilly’s first major expansion into the psychedelic drug...
